comprehensive -WSS

comprehensive

author：Wikipedia 2025-10-02 19:19:27 - browse：89

Most everything is looking up for Orexo, the company reported on its second quarter earnings call on Tuesday. That is, everything but its digital therapies pipeline.

The Swedish pharmaceutical company, which makes almost all of its money from U.S. sales of its drug for opioid dependence, notched a number of important victories in the quarter: It successfully defended its patents in a case against Sun Pharmaceuticals, it resolved a packaging issue that was holding up the approval of its long-acting rescue medication, and it grew revenues for Zubsolv, its most important product. The company trimmed its losses to 12.6 million SEK, or $1.2 million, and executives reported that with fewer one-time expenses on the horizon, profitability was “in sight.”

“We are at an exciting turning point for the company and I hope our self confidence and optimism is something that you can share,” CEO Nikolaj Sørensen said on the company’s earnings call while cautioning that “there’s a lot more work to be done.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Will General Catalyst be the first of many hospital takeovers?

explore

WSS

The Sacklers, horror, and ‘The Fall of the House of Usher’

Free speech concerns arise in wake of journal editor Eisen's firing

Extreme heat events are a public health emergency

Merck to buy EyeBio, maker of eye drug, as it grows pipeline

Study: New antibiotic targets gonorrhea as well as last existing drug

Childbirth

explore

comprehensive

entertainment

DIEP, the 'gold standard' of breast reconstruction, is under threat

STAT Executive Editor Rick Berke on STAT's 8th birthday

Affirmative action in medical school literally saved lives

Will General Catalyst be the first of many hospital takeovers?

ChatGPT in medicine: STAT answers readers' burning questions

Study: New antibiotic targets gonorrhea as well as last existing drug

Moonlake's readout produced a cash windfall. Risks remain

Senate panel clears PBM, hopsital reforms

Moonlake's readout produced a cash windfall. Risks remain

Senate panel clears PBM, hopsital reforms

focus

FDA approves Recor Medical high blood pressure device

Gene therapies for deafness raise the question: Do deaf people want a 'cure'?

Abortion clinic in Cancun will cater to Americans

Study: New antibiotic targets gonorrhea as well as last existing drug

Merck to buy EyeBio, maker of eye drug, as it grows pipeline

Biotech incubator Curie.Bio graduates its first startup

explore

Wikipedia

focus

focus